Ideaya Biosciences Net Worth
Ideaya Biosciences Net Worth Breakdown | IDYA |
Ideaya Biosciences Net Worth Analysis
Ideaya Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Ideaya Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Ideaya Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Ideaya Biosciences' net worth analysis. One common approach is to calculate Ideaya Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Ideaya Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Ideaya Biosciences' net worth. This approach calculates the present value of Ideaya Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Ideaya Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Ideaya Biosciences' net worth. This involves comparing Ideaya Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Ideaya Biosciences' net worth relative to its peers.
To determine if Ideaya Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ideaya Biosciences' net worth research are outlined below:
| Ideaya Biosciences appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 7 M. Net Loss for the year was (274.48 M) with loss before overhead, payroll, taxes, and interest of (315.75 M). | |
| Ideaya Biosciences currently holds about 268.62 M in cash with (247.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.83. | |
| Ideaya Biosciences has a very weak financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: IDEAYA Biosciences, Inc. added to Russell 3000 Value Index - MarketScreener |
Ideaya Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ideaya Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ideaya Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Ideaya Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ideaya Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ideaya Biosciences backward and forwards among themselves. Ideaya Biosciences' institutional investor refers to the entity that pools money to purchase Ideaya Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2025-03-31 | 2.1 M | Pictet Asset Manangement Sa | 2025-03-31 | 1.8 M | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 1.7 M | Citadel Advisors Llc | 2025-03-31 | 1.5 M | Ra Capital Management, Llc | 2025-03-31 | 1.3 M | Fiera Capital Corporation | 2025-03-31 | 1.2 M | Adage Capital Partners Gp Llc | 2025-03-31 | 1.2 M | Bank Of America Corp | 2025-03-31 | 1.2 M | Baker Bros Advisors Lp | 2025-03-31 | 1.1 M | Fmr Inc | 2025-03-31 | 13.1 M | Blackrock Inc | 2025-03-31 | 9.2 M |
Follow Ideaya Biosciences' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.94 B.Evaluate Ideaya Biosciences' management efficiency
Ideaya Biosciences has return on total asset (ROA) of (0.2184) % which means that it has lost $0.2184 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3134) %, meaning that it created substantial loss on money invested by shareholders. Ideaya Biosciences' management efficiency ratios could be used to measure how well Ideaya Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. At present, Ideaya Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 422 M, whereas Non Currrent Assets Other are forecasted to decline to about 587.1 K.The strategic vision of Ideaya Biosciences management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Enterprise Value Revenue 181.2888 | Revenue | Quarterly Revenue Growth 0.785 | Revenue Per Share 0.082 | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ideaya Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ideaya Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ideaya Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ideaya Biosciences time-series forecasting models is one of many Ideaya Biosciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ideaya Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Ideaya Biosciences Earnings per Share Projection vs Actual
Ideaya Biosciences Corporate Management
| Mick OQuigley | Chief Development | Profile | |
| Stu Dorman | Chief Officer | Profile | |
| Paul Stone | CFO VP | Profile | |
| Jasgit MD | Senior Development | Profile | |
| JD Esq | Chief Secretary | Profile | |
| Matthew MD | VP Oncology | Profile | |
| Esq JD | Gen VP | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ideaya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Ideaya Stock refer to our How to Trade Ideaya Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ideaya Biosciences. If investors know Ideaya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ideaya Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.65) | Revenue Per Share 0.082 | Quarterly Revenue Growth 0.785 | Return On Assets (0.22) | Return On Equity |
The market value of Ideaya Biosciences is measured differently than its book value, which is the value of Ideaya that is recorded on the company's balance sheet. Investors also form their own opinion of Ideaya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ideaya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ideaya Biosciences' market value can be influenced by many factors that don't directly affect Ideaya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ideaya Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ideaya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ideaya Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.